{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:37:06Z","timestamp":1788255426295,"version":"build-2803163510"},"reference-count":119,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.vaccine.2006.11.037","type":"journal-article","created":{"date-parts":[[2006,11,30]],"date-time":"2006-11-30T14:44:54Z","timestamp":1164897894000},"page":"1923-1934","source":"Crossref","is-referenced-by-count":43,"title":["Status and challenges of filovirus vaccines"],"prefix":"10.1016","volume":"25","author":[{"given":"Douglas S.","family":"Reed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansour","family":"Mohamadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.vaccine.2006.11.037_bib1","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1055\/s-0028-1105103","article-title":"Isolation and identification of the \u201cMarburg virus\u201d","volume":"93","author":"Siegert","year":"1968","journal-title":"Dtsch Med Wochenschr"},{"issue":"51","key":"10.1016\/j.vaccine.2006.11.037_bib2","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1055\/s-0028-1106144","article-title":"On the etiology of an unknown human infection originating from monkeys","volume":"92","author":"Siegert","year":"1967","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.vaccine.2006.11.037_bib3","unstructured":"Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO\/International Study Team. Bull World Health Org 1978:56(2);247\u201370."},{"key":"10.1016\/j.vaccine.2006.11.037_bib4","unstructured":"Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Org 1978;56(2):271\u201393."},{"key":"10.1016\/j.vaccine.2006.11.037_bib5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-3-642-59949-1_5","article-title":"Ebola virus outbreaks in the Ivory Coast and Liberia, 1994\u20131995","volume":"235","author":"Le Guenno","year":"1999","journal-title":"Curr Top Microbiol Immunol"},{"issue":"8688","key":"10.1016\/j.vaccine.2006.11.037_bib6","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/0140-6736(90)90737-P","article-title":"Preliminary report: isolation of Ebola virus from monkeys imported to USA","volume":"335","author":"Jahrling","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2006.11.037_bib7","unstructured":"Viral haemorrhagic fever\/Marburg, Democratic Republic of the Congo. Wkly Epidemiol Rec 1999;74(20):157\u20138."},{"key":"10.1016\/j.vaccine.2006.11.037_bib8","unstructured":"Outbreak of Marburg virus hemorrhagic fever-Angola, October 1, 2004\u2013March 29, 2005. MMWR Morb Mortal Wkly Rep 2005;54(12):308\u20139."},{"issue":"7068","key":"10.1016\/j.vaccine.2006.11.037_bib9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/438575a","article-title":"Fruit bats as reservoirs of Ebola virus","volume":"438","author":"Leroy","year":"2005","journal-title":"Nature"},{"issue":"5656","key":"10.1016\/j.vaccine.2006.11.037_bib10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1126\/science.1092528","article-title":"Multiple Ebola virus transmission events and rapid decline of central African wildlife","volume":"303","author":"Leroy","year":"2004","journal-title":"Science"},{"issue":"6932","key":"10.1016\/j.vaccine.2006.11.037_bib11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nature01566","article-title":"Catastrophic ape decline in western equatorial Africa","volume":"422","author":"Walsh","year":"2003","journal-title":"Nature"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2006.11.037_bib12","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1086\/514296","article-title":"Ebola virus outbreak among wild chimpanzees living in a rain forest of Cote d\u2019Ivoire","volume":"179","author":"Formenty","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2006.11.037_bib13","unstructured":"Alibek K, Handelman S. Biohazard: The chilling true story of the Largest Covert Biological Weapons Program in the World, told from the inside by the man who ran it. Random House, New York, NY; 1999."},{"key":"10.1016\/j.vaccine.2006.11.037_bib14","unstructured":"Possession, use, and transfer of select agents and toxins. Interim final rule. Fed Regist 2002;67(240):76886\u2013905."},{"issue":"5","key":"10.1016\/j.vaccine.2006.11.037_bib15","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1084\/jem.20011500","article-title":"Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses","volume":"195","author":"Bavari","year":"2002","journal-title":"J Exp Med"},{"issue":"23","key":"10.1016\/j.vaccine.2006.11.037_bib16","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.vaccine.2004.11.070","article-title":"Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections","volume":"23","author":"Swenson","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.11.037_bib17","first-page":"159","article-title":"The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis","volume":"15","author":"Feldmann","year":"1999","journal-title":"Arch Virol Suppl"},{"issue":"5458","key":"10.1016\/j.vaccine.2006.11.037_bib18","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1126\/science.287.5458.1664","article-title":"Epitopes involved in antibody-mediated protection from Ebola virus","volume":"287","author":"Wilson","year":"2000","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.vaccine.2006.11.037_bib19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1006\/viro.1998.9367","article-title":"Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates","volume":"251","author":"Hevey","year":"1998","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2006.11.037_bib20","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0042-6822(03)00416-1","article-title":"Characterization of monoclonal antibodies to Marburg virus (strain Musoke) glycoprotein and identification of two protective epitopes","volume":"314","author":"Hevey","year":"2003","journal-title":"Virology"},{"issue":"5353","key":"10.1016\/j.vaccine.2006.11.037_bib21","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1126\/science.279.5353.1034","article-title":"Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins","volume":"279","author":"Yang","year":"1998","journal-title":"Science"},{"issue":"Pt 12","key":"10.1016\/j.vaccine.2006.11.037_bib22","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1099\/0022-1317-82-12-2839","article-title":"Biosynthesis and role of filoviral glycoproteins","volume":"82","author":"Feldmann","year":"2001","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2006.11.037_bib23","first-page":"115","article-title":"Experimental infection of cynomolgus macaques with Ebola-Reston filoviruses from the 1989\u20131990 U.S. epizootic","volume":"11","author":"Jahrling","year":"1996","journal-title":"Arch Virol Suppl"},{"issue":"4","key":"10.1016\/j.vaccine.2006.11.037_bib24","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/infdis\/166.4.753","article-title":"Pathogenic potential of filoviruses: role of geographic origin of primate host and virus strain","volume":"166","author":"Fisher-Hoch","year":"1992","journal-title":"J Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2006.11.037_bib25","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1086\/514285","article-title":"Human infection due to Ebola virus, subtype Cote d\u2019Ivoire: clinical and biologic presentation","volume":"179","author":"Formenty","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2006.11.037_bib26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/978-3-642-59949-1_11","article-title":"Immune response to filovirus infections","volume":"235","author":"Ignatyev","year":"1999","journal-title":"Curr Top Microbiol Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2006.11.037_bib27","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/BF01322532","article-title":"The complete nucleotide sequence of the Popp (1967) strain of Marburg virus: a comparison with the Musoke (1980) strain","volume":"140","author":"Bukreyev","year":"1995","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2006.11.037_bib28","first-page":"101","article-title":"Characterization of a new Marburg virus isolated from a 1987 fatal case in Kenya","volume":"11","author":"Johnson","year":"1996","journal-title":"Arch Virol Suppl"},{"issue":"13","key":"10.1016\/j.vaccine.2006.11.037_bib29","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1128\/JVI.00069-06","article-title":"Marburgvirus genomics and association with a large hemorrhagic Fever outbreak in angola","volume":"80","author":"Towner","year":"2006","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2006.11.037_bib30","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/oxfordjournals.bmb.a011719","article-title":"Filoviral haemorrhagic fevers","volume":"54","author":"Khan","year":"1998","journal-title":"Br Med Bull"},{"issue":"1","key":"10.1016\/j.vaccine.2006.11.037_bib31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1046\/j.1365-2249.2002.01800.x","article-title":"Inflammatory responses in Ebola virus-infected patients","volume":"128","author":"Baize","year":"2002","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2006.11.037_bib32","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/7422","article-title":"Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients","volume":"5","author":"Baize","year":"1999","journal-title":"Nat Med"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2006.11.037_bib33","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1086\/514321","article-title":"Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995","volume":"179","author":"Ksiazek","year":"1999","journal-title":"J Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2006.11.037_bib34","doi-asserted-by":"crossref","first-page":"S188","DOI":"10.1086\/514283","article-title":"Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection","volume":"179","author":"Villinger","year":"1999","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2006.11.037_bib35","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/BF01734141","article-title":"Spermatogenic transmission of the \u201cMarburg virus\u201d (causes of \u201cMarburg simian disease\u201d)","volume":"46","author":"Martini","year":"1968","journal-title":"Klin Wochenschr"},{"issue":"11","key":"10.1016\/j.vaccine.2006.11.037_bib36","first-page":"521","article-title":"Detection of the \u201cMarburg Virus\u201d in patients","volume":"13","author":"Siegert","year":"1968","journal-title":"Ger Med Mon"},{"issue":"2 Suppl.","key":"10.1016\/j.vaccine.2006.11.037_bib37","first-page":"23","article-title":"Lessons from the Marburg virus epidemic in Durba, Democratic Republic of the Congo (1998\u20132000)","volume":"60","author":"Zeller","year":"2000","journal-title":"Med Trop (Mars)"},{"issue":"19","key":"10.1016\/j.vaccine.2006.11.037_bib38","doi-asserted-by":"crossref","first-page":"9659","DOI":"10.1128\/JVI.00959-06","article-title":"Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine","volume":"80","author":"Daddario-DiCaprio","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2006.11.037_bib39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-642-59949-1_8","article-title":"Experimental filovirus infections","volume":"235","author":"Fisher-Hoch","year":"1999","journal-title":"Curr Top Microbiol Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2006.11.037_bib40","first-page":"158","article-title":"Certain pathogenetic characteristics of a disease in monkeys in infected with the Marburg virus by an airborne route","volume":"40","author":"Lub","year":"1995","journal-title":"Vopr Virusol"},{"issue":"3","key":"10.1016\/j.vaccine.2006.11.037_bib41","first-page":"119","article-title":"Clinical-virusological characteristics of disease in guinea pigs, infected by the Marburg virus aerogenically","volume":"40","author":"Lub","year":"1995","journal-title":"Vopr Virusol"},{"issue":"11","key":"10.1016\/j.vaccine.2006.11.037_bib42","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1007\/BF01718224","article-title":"Respiratory Marburg virus infection in guinea pigs","volume":"141","author":"Ryabchikova","year":"1996","journal-title":"Arch Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2006.11.037_bib43","first-page":"32","article-title":"Survival of Marburg virus infectivity on contaminated surfaces and in aerosols","volume":"41","author":"Belanov","year":"1996","journal-title":"Vopr Virusol"},{"issue":"4","key":"10.1016\/j.vaccine.2006.11.037_bib44","first-page":"227","article-title":"Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus","volume":"76","author":"Johnson","year":"1995","journal-title":"Int J Exp Pathol"},{"issue":"3","key":"10.1016\/j.vaccine.2006.11.037_bib45","first-page":"113","article-title":"Experimental Ebola fever in Macaca mulatta","volume":"40","author":"P\u2019Iankov","year":"1995","journal-title":"Vopr Virusol"},{"issue":"3","key":"10.1016\/j.vaccine.2006.11.037_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/bsp.2004.2.186","article-title":"Marburg and Ebola viruses as aerosol threats","volume":"2","author":"Leffel","year":"2004","journal-title":"Biosecurity Bioterrorism: Biodefense Strat Pract Sci"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2006.11.037_bib47","doi-asserted-by":"crossref","first-page":"S203","DOI":"10.1086\/514305","article-title":"Pathogenesis of experimental Ebola virus infection in guinea pigs","volume":"179","author":"Connolly","year":"1999","journal-title":"J Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2006.11.037_bib48","doi-asserted-by":"crossref","first-page":"S248","DOI":"10.1086\/514292","article-title":"A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever","volume":"179","author":"Bray","year":"1999","journal-title":"J Infect Dis"},{"issue":"Pt 6","key":"10.1016\/j.vaccine.2006.11.037_bib49","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1099\/0022-1317-82-6-1365","article-title":"The role of the Type I interferon response in the resistance of mice to filovirus infection","volume":"82","author":"Bray","year":"2001","journal-title":"J Gen Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2006.11.037_bib50","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1128\/JVI.77.2.1069-1074.2003","article-title":"Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses","volume":"77","author":"Takada","year":"2003","journal-title":"J Virol"},{"issue":"18","key":"10.1016\/j.vaccine.2006.11.037_bib51","doi-asserted-by":"crossref","first-page":"9176","DOI":"10.1128\/JVI.76.18.9176-9185.2002","article-title":"Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells","volume":"76","author":"Rao","year":"2002","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2006.11.037_bib52","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0166-3542(02)00018-9","article-title":"3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice","volume":"55","author":"Bray","year":"2002","journal-title":"Antiviral Res"},{"issue":"10","key":"10.1016\/j.vaccine.2006.11.037_bib53","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1128\/JVI.75.10.4649-4654.2001","article-title":"Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication","volume":"75","author":"Gupta","year":"2001","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2006.11.037_bib54","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1006\/viro.2001.1012","article-title":"Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins","volume":"286","author":"Wilson","year":"2001","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.vaccine.2006.11.037_bib55","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.4049\/jimmunol.175.2.1184","article-title":"Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection","volume":"175","author":"Warfield","year":"2005","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2006.11.037_bib56","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1084\/jem.20032141","article-title":"Role of natural killer cells in innate protection against lethal ebola virus infection","volume":"200","author":"Warfield","year":"2004","journal-title":"J Exp Med"},{"issue":"26","key":"10.1016\/j.vaccine.2006.11.037_bib57","doi-asserted-by":"crossref","first-page":"15889","DOI":"10.1073\/pnas.2237038100","article-title":"Ebola virus-like particles protect from lethal Ebola virus infection","volume":"100","author":"Warfield","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"22","key":"10.1016\/j.vaccine.2006.11.037_bib58","doi-asserted-by":"crossref","first-page":"14189","DOI":"10.1128\/JVI.79.22.14189-14196.2005","article-title":"Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins","volume":"79","author":"Olinger","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2006.11.037_bib59","unstructured":"Reed DS, in preparation."},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2006.11.037_bib60","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0264-410X(01)00353-X","article-title":"Marburg virus vaccines: comparing classical and new approaches","volume":"20","author":"Hevey","year":"2001","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2006.11.037_bib61","first-page":"153","article-title":"The effect of the methods for producing an experimental Marburg virus infection on the characteristics of the course of the disease in green monkeys","volume":"37","author":"Bazhutin","year":"1992","journal-title":"Vopr Virusol"},{"issue":"5","key":"10.1016\/j.vaccine.2006.11.037_bib62","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/infdis\/152.5.887","article-title":"Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola)","volume":"152","author":"Fisher-Hoch","year":"1985","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2006.11.037_bib63","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/path.1711250303","article-title":"The pathology of experimental Ebola virus infection in monkeys","volume":"125","author":"Baskerville","year":"1978","journal-title":"J Pathol"},{"issue":"4","key":"10.1016\/j.vaccine.2006.11.037_bib64","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/jcpa.2001.0503","article-title":"Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus","volume":"125","author":"Bray","year":"2001","journal-title":"J Comp Pathol"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2006.11.037_bib65","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1086\/514293","article-title":"An analysis of features of pathogenesis in two animal models of Ebola virus infection","volume":"179","author":"Ryabchikova","year":"1999","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2006.11.037_bib66","first-page":"435","article-title":"The sensitivity of different experimental animals to the Marburg virus","volume":"36","author":"Gonchar","year":"1991","journal-title":"Vopr Virusol"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2006.11.037_bib67","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1086\/514284","article-title":"Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit","volume":"179","author":"Dowell","year":"1999","journal-title":"J Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2006.11.037_bib68","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1086\/514314","article-title":"Epidemiology of Ebola (subtype Reston) virus in the Philippines, 1996","volume":"179","author":"Miranda","year":"1999","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2006.11.037_bib69","first-page":"275","article-title":"Stability of Marburg virus to lyophilization process and subsequent storage at different temperatures","volume":"41","author":"Frolov","year":"1996","journal-title":"Vopr Virusol"},{"issue":"2","key":"10.1016\/j.vaccine.2006.11.037_bib70","first-page":"140","article-title":"Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure","volume":"120","author":"Jaax","year":"1996","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.vaccine.2006.11.037_bib71","unstructured":"New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule. Fed Regist 2002;67(105):37988\u201398."},{"issue":"2","key":"10.1016\/j.vaccine.2006.11.037_bib72","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/0035-9203(78)90058-5","article-title":"Ebola haemorrhagic fever: experimental infection of monkeys","volume":"72","author":"Bowen","year":"1978","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2006.11.037_bib73","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1006\/viro.1995.1458","article-title":"Attenuated mutations of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1","volume":"212","author":"Davis","year":"1995","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2006.11.037_bib74","first-page":"13","article-title":"The immunity indices of animals immunized with the inactivated Marburg virus after infection with homologous virus","volume":"39","author":"Ignat\u2019ev","year":"1994","journal-title":"Vopr Virusol"},{"issue":"1\u20133","key":"10.1016\/j.vaccine.2006.11.037_bib75","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0168-1656(95)00104-2","article-title":"Inactivated Marburg virus elicits a nonprotective immune response in Rhesus monkeys","volume":"44","author":"Ignatyev","year":"1996","journal-title":"J Biotechnol"},{"issue":"2","key":"10.1016\/j.vaccine.2006.11.037_bib76","first-page":"74","article-title":"The effect of some physical and chemical factors on inactivation of the Ebola virus","volume":"40","author":"Chepurnov","year":"1995","journal-title":"Vopr Virusol"},{"issue":"5","key":"10.1016\/j.vaccine.2006.11.037_bib77","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3201\/eid0805.010284","article-title":"Evaluation in nonhuman primates of vaccines against Ebola virus","volume":"8","author":"Geisbert","year":"2002","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2006.11.037_bib78","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1006\/viro.1997.8883","article-title":"Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants","volume":"239","author":"Hevey","year":"1997","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.vaccine.2006.11.037_bib79","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-1702(02)00338-6","article-title":"Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs","volume":"92","author":"Mellquist-Riemenschneider","year":"2003","journal-title":"Virus Res"},{"issue":"25\u201326","key":"10.1016\/j.vaccine.2006.11.037_bib80","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1016\/S0264-410X(03)00362-1","article-title":"Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus","volume":"21","author":"Riemenschneider","year":"2003","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2006.11.037_bib81","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nm0198-037","article-title":"Immunization for Ebola virus infection","volume":"4","author":"Xu","year":"1998","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.vaccine.2006.11.037_bib82","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1001\/jama.291.5.549","article-title":"Ebola vaccines tested in humans, monkeys","volume":"291","author":"Vastag","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2006.11.037_bib83","first-page":"99","article-title":"A molecular genetic approach to the study of Venezuelan equine encephalitis virus pathogenesis","volume":"9","author":"Davis","year":"1994","journal-title":"Arch Virol Suppl"},{"issue":"2","key":"10.1016\/j.vaccine.2006.11.037_bib84","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1089\/088922203762688649","article-title":"Characterization and selection of HIV-1 subtype C isolates for use in vaccine development","volume":"19","author":"Williamson","year":"2003","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"3","key":"10.1016\/j.vaccine.2006.11.037_bib85","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/514240","article-title":"Immunologic interference from sequential administration of live attenuated alphavirus vaccines","volume":"177","author":"McClain","year":"1998","journal-title":"J Infect Dis"},{"issue":"6812","key":"10.1016\/j.vaccine.2006.11.037_bib86","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/35046108","article-title":"Development of a preventive vaccine for Ebola virus infection in primates","volume":"408","author":"Sullivan","year":"2000","journal-title":"Nature"},{"issue":"6949","key":"10.1016\/j.vaccine.2006.11.037_bib87","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nature01876","article-title":"Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates","volume":"424","author":"Sullivan","year":"2003","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.vaccine.2006.11.037_bib88","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1371\/journal.pmed.0030177","article-title":"Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs","volume":"3","author":"Sullivan","year":"2006","journal-title":"PLoS Med"},{"issue":"9","key":"10.1016\/j.vaccine.2006.11.037_bib89","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/sj.gt.3300994","article-title":"Immune responses to adenovirus and adeno-associated virus in humans","volume":"6","author":"Chirmule","year":"1999","journal-title":"Gene Ther"},{"issue":"2","key":"10.1016\/j.vaccine.2006.11.037_bib90","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.virol.2005.10.042","article-title":"Chimpanzee adenovirus vaccine protects against Zaire Ebola virus","volume":"346","author":"Kobinger","year":"2006","journal-title":"Virology"},{"issue":"Pt 1","key":"10.1016\/j.vaccine.2006.11.037_bib91","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1099\/vir.0.81445-0","article-title":"Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors","volume":"87","author":"Barratt-Boyes","year":"2006","journal-title":"J Gen Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2006.11.037_bib92","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.micinf.2005.05.023","article-title":"Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis","volume":"8","author":"Appaiahgari","year":"2006","journal-title":"Microbes Infect"},{"issue":"1","key":"10.1016\/j.vaccine.2006.11.037_bib93","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1128\/JVI.77.1.799-803.2003","article-title":"Overcoming immunity to a viral vaccine by DNA priming before vector boosting","volume":"77","author":"Yang","year":"2003","journal-title":"J Virol"},{"issue":"7090","key":"10.1016\/j.vaccine.2006.11.037_bib94","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature04721","article-title":"Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity","volume":"441","author":"Roberts","year":"2006","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.vaccine.2006.11.037_bib95","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.4049\/jimmunol.172.10.6290","article-title":"Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity","volume":"172","author":"Barouch","year":"2004","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2006.11.037_bib96","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat Med"},{"issue":"9520","key":"10.1016\/j.vaccine.2006.11.037_bib97","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(06)68546-2","article-title":"Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment","volume":"367","author":"Daddario-DiCaprio","year":"2006","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2006.11.037_bib98","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1006\/viro.1996.0271","article-title":"Persistence of vesicular stomatitis virus New Jersey RNA in convalescent hamsters","volume":"219","author":"Barrera","year":"1996","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.vaccine.2006.11.037_bib99","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1006\/viro.1996.0275","article-title":"Vesicular stomatitis New Jersey virus RNA persists in cattle following convalescence","volume":"219","author":"Letchworth","year":"1996","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.vaccine.2006.11.037_bib100","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1128\/JVI.80.5.2267-2279.2006","article-title":"A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge","volume":"80","author":"Bukreyev","year":"2006","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2006.11.037_bib101","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S1286-4579(03)00095-9","article-title":"Molecular mechanisms of filovirus cellular trafficking","volume":"5","author":"Aman","year":"2003","journal-title":"Microbes Infect"},{"issue":"2","key":"10.1016\/j.vaccine.2006.11.037_bib102","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.virol.2004.05.025","article-title":"Ebola and Marburg virus-like particles activate human myeloid dendritic cells","volume":"326","author":"Bosio","year":"2004","journal-title":"Virology"},{"issue":"25\u201326","key":"10.1016\/j.vaccine.2006.11.037_bib103","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1016\/j.vaccine.2004.01.063","article-title":"Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection","volume":"22","author":"Warfield","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.11.037_bib104","first-page":"259","article-title":"SIV infection of macaques: a model for AIDS vaccine development","volume":"72","author":"Gardner","year":"1990","journal-title":"Dev Biol Stand"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2006.11.037_bib105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0165-2478(96)02555-2","article-title":"SIVagm infection of its natural African green monkey host","volume":"51","author":"Norley","year":"1996","journal-title":"Immunol Lett"},{"issue":"6","key":"10.1016\/j.vaccine.2006.11.037_bib106","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1128\/CDLI.6.6.953-958.1999","article-title":"Comparison and characterization of immunoglobulin G subclasses among primate species","volume":"6","author":"Shearer","year":"1999","journal-title":"Clin Diagn Lab Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2006.11.037_bib107","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1538\/expanim.49.97","article-title":"Upgrading of flow cytometric analysis for absolute counts, cytokines and other antigenic molecules of cynomolgus monkeys (Macaca fascicularis) by using anti-human cross-reactive antibodies","volume":"49","author":"Yoshino","year":"2000","journal-title":"Exp Anim"},{"issue":"1","key":"10.1016\/j.vaccine.2006.11.037_bib108","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/(SICI)1097-0320(19990901)37:1<41::AID-CYTO5>3.0.CO;2-4","article-title":"CD56 identifies monocytes and not natural killer cells in rhesus macaques","volume":"37","author":"Carter","year":"1999","journal-title":"Cytometry"},{"issue":"6","key":"10.1016\/j.vaccine.2006.11.037_bib109","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/intimm\/9.6.843","article-title":"CD4 and CD8 expressions in African green monkey helper T lymphocytes: implication for resistance to SIV infection","volume":"9","author":"Murayama","year":"1997","journal-title":"Int Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2006.11.037_bib110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/030098589202900107","article-title":"A comparative study of natural killer cell activity, lymphoproliferation, and cell phenotypes in nonhuman primates","volume":"29","author":"Rappocciolo","year":"1992","journal-title":"Vet Pathol"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2006.11.037_bib111","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1086\/514298","article-title":"Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee","volume":"179","author":"Mupapa","year":"1999","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2006.11.037_bib112","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1128\/JVI.73.7.6024-6030.1999","article-title":"Ebola virus can be effectively neutralized by antibody produced in natural human infection","volume":"73","author":"Maruyama","year":"1999","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2006.11.037_bib113","doi-asserted-by":"crossref","first-page":"6408","DOI":"10.1128\/JVI.76.12.6408-6412.2002","article-title":"Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody","volume":"76","author":"Parren","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2006.11.037_bib114","first-page":"135","article-title":"Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses","volume":"11","author":"Jahrling","year":"1996","journal-title":"Arch Virol Suppl"},{"issue":"5","key":"10.1016\/j.vaccine.2006.11.037_bib115","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1128\/JVI.75.5.2324-2330.2001","article-title":"Infectivity-enhancing antibodies to Ebola virus glycoprotein","volume":"75","author":"Takada","year":"2001","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2006.11.037_bib116","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1006\/viro.2001.1279","article-title":"Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections","volume":"293","author":"Geisbert","year":"2002","journal-title":"Virology"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2006.11.037_bib117","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jim.2003.12.015","article-title":"Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system","volume":"286","author":"Crotty","year":"2004","journal-title":"J Immunol Methods"},{"issue":"8207","key":"10.1016\/j.vaccine.2006.11.037_bib118","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/S0140-6736(80)92352-1","article-title":"Inactivated vaccine for Ebola virus efficacious in guineapig model","volume":"2","author":"Lupton","year":"1980","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2006.11.037_bib119","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1006\/viro.1998.9176","article-title":"DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge","volume":"246","author":"Vanderzanden","year":"1998","journal-title":"Virology"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06012308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06012308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T04:35:42Z","timestamp":1587270942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X06012308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":119,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S0264410X06012308"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2006.11.037","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}